The immunogenicity of intranasal adjuvanted pandemic avian influenza vaccine in murine model by Pham, Nam Cong
 
 
 
 
The immunogenicity of an intranasal  
adjuvanted pandemic avian influenza vaccine  
in murine model 
 
 
 
by 
Nam Cong Pham 
 
 
 
 
 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements for the degree of 
Master of Science  
 
 
 
 
Centre of Pharmacy and Influenza centre,  
and the Gade Institute 
University of Bergen 
 
July 2009 
 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
Abstract 
 
Influenza vaccination remains the primary method for the prevention of influenza and 
the severe complications related to the disease. Development of an intranasal 
vaccination strategy will not only prevent the disease but also block the viral entry to the 
host and the horizontal transmission. Thus, intranasal pandemic vaccines may induce of 
humoral and cellular immune responses at the both systemic and mucosal levels. In this 
study, we investigated and compared the mucosal, humoral and cytokine immune 
responses induced in mice after intranasal vaccination with subunit influenza vaccine 
formulated with or without a novel “c-di-GMP” adjuvant.  
  
Forty BALB/c mice were divided into two equally sized groups. Mice were vaccinated 
intranasally with two doses at three week interval of 15 µg of A/Vietnam/1194/2004 
(H5N1) non-adjuvanted subunit vaccine or c-di-GMP adjuvanted antigen. Nasal wash 
and serum samples were collected at various time points after vaccination and used in 
the ELISA, whilst sera was in addition used in the HI assay. Supernatants from in vitro 
activated splenocytes were used to determine the concentration of IFN-γ, IL-2, IL-4, IL-
5, IL-10 and IL-17 by Bio-plex bead immunoassay.   
 
In this study, we showed that intranasal immunisation of subunit vaccine formulated 
with c-di-GMP adjuvant induced a more rapid mucosal and humoral immune response 
than the subunit vaccine administered alone. Additionally, the study showed that the 
presence of the mucosal adjuvant elicited a Th1 profile, which suggests promotion of 
cell-mediated immune response. On the other hand, immunization with subunit vaccine 
alone induced low antibody responses and a Th2-type immune response. 
The results obtained in this study indicate that c-di-GMP is a promising adjuvant for the 
future development of intranasal pandemic influenza vaccines. 
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1. Introduction 
 
1.1 Introduction to influenza 
Influenza is a highly contagious acute respiratory infection and is one of the major 
causes of disease worldwide. Many years of research have produced extensive 
knowledge about the influenza virus, vaccines and immunity, but the virus is still 
capable of surprising us as witnessed by the avian influenza sporadic human 
transmission and swine origin influenza A (H1N1) ongoing pandemic. In annual 
influenza epidemics 5-15 % of the world population are infected with upper respiratory 
tract infection resulting in between 250 000 and 500 000 deaths [1]. Influenza infections 
in high-risk groups (elderly and chronically ill individuals) cause the highest number of 
hospitalizations and deaths [1]. At unpredictable time intervals, a novel influenza A 
virus with the ability to infect humans may emerge and cause a worldwide influenza 
outbreak (pandemic). This has occurred three times during the 20th century. The Spanish 
flu pandemic (1918) was caused by influenza A virus H1N1 and had the highest 
mortality, causing 40-50 million deaths worldwide. The Asian flu pandemic (1957) was 
caused by the virus subtype H2N2, which resulted in a total number of deaths that 
probably exceeded 1 million people. The Hong Kong flu pandemic (1968-70), caused by 
virus type H3N2, had a lower death rate estimated at 500,000 deaths [2]. Now 41 years 
later, the WHO ha declared a swine origin influenza A(H1N1) pandemic. 
 
In 1997, 18 people were infected with H5N1 from infected poultry and six of these died. 
The Hong Kong authorities took swift action and destroyed all poultry in the province 
stopping further human infection. In mid-2003, the outbreak of a highly pathogenic 
H5N1 influenza virus began in south-east Asia. More than 120 million birds died or 
were destroyed after the initial spread of H5N1 in poultry [5]. To date 433 people have 
been infected mainly through direct contact with infected birds and the death rate is 
approximately 60%. All prerequisites for an influenza pandemic defined by WHO have 
been met H5N1, except efficient human-to-human transmission. The human infection by 
H5N1 led to an extensive research into influenza and new pandemic vaccine candidates 
[3, 4]. 
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Figure 1.1 Ecology of influenza A.  
Subtypes shown in red are most likely candidates 
to start the next pandemic. Adapted from [8]. 
 
 
1.2 The influenza virus  
Influenza virus belongs to the family 
Orthomyxoviridae and is divided into 
three genera, namely influenza A, B and 
C. Such a division is based on antigenic 
differences in their internal proteins, 
nucleoproteins (NP) and matrix (M) [6]. 
The current thesis will only discuss 
influenza A virus as this is the focus of 
the work. Influenza A is further 
classified into subtypes which is based on 
its surface glycoproteins, HA 
(Haemagglutinin) and NA 
(Neuraminidase). To date, there are 
sixteen known subtypes of HA (H1-16) 
and nine subtypes of NA (N1-9), all of which are found in birds. Influenza A viruses are 
found in a whole range of vertebrates with waterfowl as the main reservoir [7], see fig. 
1.1. 
 
1.2.1 Nomenclature 
The nomenclature system for influenza virus is defined by the WHO as follows: type of 
virus, virus host (if non human), geographical isolation area, isolation number, the year 
isolation, and the subtypes of HA and NA in parenthesis. For instance, 
A/duck/Hunan/795/2002 (H5N1) which describes that it is influenza A virus, isolated 
from chicken in Hong Kong in 1997, with an isolation number 33 and subtype H5N1. 
The same nomenclature system is used for humans, but the host is omitted, e.g. 
A/Brisbane/10/2007 (H3N2) [73].  
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Figure 1.2 A schematic figure of the influenza A virus 
that shows the RNA segments and their expressed 
proteins and where these proteins are localised in the 
virus. HA, NA and M2 protein are embedded in the 
lipid layer. M1 protein is detected beneath the envelope. 
Nuclear export protein/non structural (NEP/NS) is also 
associated with the virus. The 
nucleoproteins/polymerases form a complex with the 
RNA [6]. 
1.2.2 Viral structure and genome 
Influenza A is an enveloped virus with a dense layer of protein spikes (HA and NA) [6]. 
Influenza A has eight negative sense ssRNA (single strand RNA) linear segments. Each 
of these segments expresses essential proteins that participate in the virus life cycle (fig. 
1.2 and table 1.1) [6]. The two major surface glycoproteins HA and NA will be 
described in more detail below.  
 
 
 
 
 
 
 
 
 
 
 
1.2.2.1 Haemagglutinin (HA) 
Haemagglutinin (fig. 1.3) is named after its ability to 
agglutinate erythrocytes (haemagglutination) [10]. The HA 
has two major functions in the virus life cycle. Firstly, HA 
binds to the sialic acid-containing receptor on the host cell 
surface bringing the virion in close proximity to the host cell 
membrane such that the infection process can be initiated. 
Secondly, HA induces the fusion of the endocytosed virion 
with the endosomal membrane allowing release of the viral 
nucleocapsid into the cytoplasm [10]. Although, there are 
differences in the HA subtypes, they all have similar 
conformation and structure [1]. The HA is the primary target 
for neutralizing antibodies. Therefore the HA is the main 
component of vaccines and current vaccines are thus 
standardised according to the HA concentration [10]. 
 
Figure 1.3 The HA is 
shown in its trimeric 
form. Modified from 
[51]. 
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1.2.2.2 Neuraminidase (NA) 
Neuraminidase is a homotetrameric glycoprotein with neuraminidase enzymatic activity. 
Each enzyme subunit consists of 453 amino acids arranged in a six β-sheet system, 
where each system is organized in four antiparallel β sheets like blades in a propeller 
[11]. The NA major functions are helping the virus to penetrate through the mucus layer 
to the respiratory epithelium [74] and the NA is also responsible for enzymatic removal 
of sialic acid from the host cell surface which allows the release of the virus from the 
host cell [75]. NA is the second most important surface antigen and is the target of 
antiviral agents, Zanamivir and Oseltamivir [12]. The NA is present in influenza 
vaccines but its concentration is not quantified. 
 
 
 
Segment 
number 
Gene product Major function 
1 Basic polymerase protein 2, 
PB2  
Part of the polymerase complex, polymerase activity, 
RNA cap binding 
2 Basic polymerase protein 1, 
PB1  
Part of the polymerase complex, transcriptase activity. 
3 Acidic polymerase, PA Part of the polymerase complex, transcriptase activity. 
4 Haemagglutinin, HA Surface glycoprotein that binds to sialic acid on the host 
cell surface, fusion with the cellular membrane. Major 
target for antibodies. 
5 Nucleoprotein, NP Encapsulates the viral RNA in the RNP. 
6 Neuraminidase, NA Release of the progeny viral particles from infected cells. 
7 Matrix protein 1, M1 
Matrix protein 2, M2 
Viral matrix protein, promotes vRNP nuclear export.  
Membrane protein that has H+ ion channel activity. 
8 Nonstructural protein 1, NS1  
Nonstructural protein 2, NS2 
(NEP) 
Regulation of cellular and viral protein expression. 
RNP nuclear export. 
Table 1.1 Influenza A gene products and their functions. Adapted from [6]. 
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1.3 Influenza epidemiology  
Influenza virus undergoes continuous antigenic variations of the surface glycoproteins, 
HA and NA, which enable the virus to re-infect its host. These antigenic variations are 
essential for the influenza evolution and survival, and arise by two mechanisms: 
antigenic drift and antigenic shift. Antigenic drift causes interpandemic influenza which 
are localized outbreaks or epidemics; whereas the latter, antigenic shift results in a 
pandemic influenza [19].  
 
1.3.1 Antigenic drift and 
epidemics 
The influenza virus genomes consist 
of RNA segments which are 
transcribed by their own RNA 
polymerase that lacks proofreading 
ability. This results in a higher 
potential for accumulation of point 
mutation in the HA and NA surface 
glycoproteins that may lead to 
changes in the antigenicity of these 
proteins, termed antigenic drift. 
Some mutations cause changes that 
permit the virus to evade immune 
recognition, neutralization by 
antibodies generated against 
previous viral strains and leading to 
repeated interpandemic outbreaks 
(fig. 1.4). Due to the antigenic drift 
in the most recent circulating 
seasonal influenza viruses A 
(H1N1), A (H3N2) and influenza B 
viruses, the vaccines’ antigen 
composition has to be annually 
adjusted [20].  
Figure 1.4 Antigenic drift. Illustration courtesy of 
“National Institute of Allergy and Infectious 
Diseases” [18]. 
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Antigenic drift leads to interpandemic outbreaks and typically new viruses prevail for 
two to five years before being replaced by a different variant [7]. Influenza is a seasonal 
respiratory disease. In the northern hemisphere, influenza outbreaks usually occur in the 
period November to April, and between May to September in the southern parts of the 
world. During the winter months in the northern hemisphere, it is believed that the low 
relative indoor humidity prolongs the survival of influenza in aerosols and may 
contribute to the seasonal pattern [20]. An epidemic is characterized when the number of 
influenza like illnesses increases above the threshold for the normal number of influenza 
like illnesses in this period [37].  
In Norway, the monitoring of the influenza activity is obtained by reports from the 
general practitioners [22]. In Norway, a seasonal influenza outbreak causes 
approximately 1300 deaths annually [29].  
 
1.3.2 Antigenic shift and 
pandemic 
Antigenic shift occurs when a novel 
influenza A virus is introduced into 
the human population. The new virus 
results in a high infection rate in the 
immunologically naïve population as 
it is antigenically distinct from the 
previously circulating strains, 
leading to a pandemic [20, 23]. This 
has occurred three times in the last 
century and a pandemic has just 
started in 2009 as described in the 
“Introduction to influenza”. Wild 
birds are the natural reservoir of all 
influenza A subtypes. Antigenic shift 
is typically a reassortment between 
human and avian viruses that caused 
the 1957 and 1968 pandemics (is 
though to occur in pigs). Another 
Fig. 1.5 Antigenic shift. Illustration courtesy of 
“National Institute of Allergy and Infectious 
Diseases” [24]. 
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mechanism for antigenic shift is the direct transmission of swine or avian influenza virus 
to humans and their establishment in the human population, see figure 1.5. By using 
phylogenic evidence, the “Spanish influenza” is thought to have been caused by the 
direct introduction of an avian virus into the human population [7]. The segmented 
nature of the virus allows for reassortment of two viruses which co-infect one cell.  
  
A pandemic is an epidemic of infectious disease that spreads throughout the world. The 
World Health Organization (WHO) has defined three prerequisites for an influenza 
pandemic [26]: 1) a novel influenza virus emerges in the general population to which it 
is immunologically naïve, 2) this novel virus must be able to replicate in humans and 
cause disease, and 3) the virus must have effective human-to-human transmission. 
 
The WHO has divided the occurrence of a pandemic into six phases (fig. 1.6). Phase six 
signifies the declaration of a new influenza pandemic. Since the 1968 influenza 
pandemic, experts at the WHO and elsewhere believe that the world is now closer to 
another pandemic. The declaration of a pandemic of swine origin influenza A(H1N1) in 
June 2009 confirmed this fear. The WHO ascertains that the world is presently in phase 
3 for H5N1: This new H5N1 influenza virus is capable of spreading from animals to 
humans but, fortunately, it does not transmit from humans to humans efficiently [27].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Phases in the development of an influenza pandemic and the current status for avian 
H5N1 virus [27]. 
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1.4 WHO surveillance system  
WHO utilizes The WHO Global Influenza Surveillance Network to monitor which 
influenza strains are the most likely potential strains to cause an outbreak during the 
next influenza season. The WHO Global Influenza Surveillance Network is mainly 
composed of National Influenza Centres (NICs) and four WHO Collaborating Centres 
(WHO CCs). NICs, which consist of 125 institutions from 96 countries, takes samples 
from 175 000 patients who have influenza-like-illness [45]. The isolates are forwarded 
to WHO CCs for antigenic and genetic analyses [45].  
 
Twice annually, the WHO recommends the strains for inclusion in influenza vaccines 
for the subsequent influenza season. Annually, approximately 500 million doses of 
influenza vaccine, based on the WHO’s recommendation are produced.  
To date, the WHO has registered 433 cases of influenza H5N1 infection with 262 
deaths. Most of the incidents have occurred in South-East Asia, Indonesia, Vietnam, 
Thailand and South China. The only other country with a substantial number of 
infection and deaths is Egypt [46]. See table 1.2. 
 
 
Year Country/Region Number of cases  Number of deaths  
2003 China, Vietnam  4 4 
2004 Thailand, Vietnam 46 32 
2005 Cambodia, China, Indonesia, Thailand, Vietnam 98 43 
2006 Azerbaijan, Cambodia, China,  Djibouti, Egypt, 
Indonesia, Iraq, Thailand, Turkey 
115 79 
2007 Cambodia, China, Egypt, Indonesia, Lao 
People’s Democratic Republic, Myanmar, 
Nigeria, Pakistan, Vietnam 
88 59 
2008 Bangladesh, Cambodia, China, Egypt, Indonesia, 
Vietnam 
44 33 
2009 China, Egypt, Vietnam 38 12 
 
Table 1.2 The number of human cases and deaths from influenza A H5N1 since 2003. Adapted from 
[46] (8th of June 2009). 
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1.5 Widespread illness 
The main route of human infection with H5N1 is direct contact with infected poultry, or 
with surfaces and objects contaminated by their faeces. Many households in rural areas 
keep small poultry flocks. These roam freely inside the homes or share the outdoor area 
with playing children and are a significant cause of infection. Moreover, many 
households in Asia depend on poultry for income and food. When signs of illness appear 
in a flock, birds will be sold or slaughtered and consumed. This is a problem as exposure 
to virus often occurs during preparation of poultry for cooking, slaughtering, butchering, 
and defeathering [3]. 
 
1.6 Clinical manifestation of influenza 
 
1.6.1 Seasonal influenza 
Influenza infection can be either symptomatic or asymptomatic, and does not cause 
persistent or latent infection [7]. Transmission of influenza virus from person to person 
occurs mainly via droplets in the air and small particles excreted when infected 
individuals cough or sneeze. The influenza virus normally infects epithelial cells of the 
upper respiratory tract. The incubation period generally is between one to four days 
[20], and the infected individual is infectious from the day symptoms occur and until 
three to five days afterwards. The clinical picture varies, but generally it is characterized 
by sudden onset of high fever, headache and severe malaise, myalgia, sore throat, non-
productive cough, and rhinitis. Healthy people recover within one to two weeks without 
requiring any medical treatment. Influenza poses a serious risk in the very young 
children (<2 years old), the elderly (>65 years old) and people suffering from medical 
conditions such as diabetes, cancer, lung disease, kidney and heart problems. Infection 
may lead to severe complications of underlying diseases, pneumonia and death in people 
within these groups and these subjects are therefore recommended for annual 
vaccination. Influenza can cause viral pneumonia or secondary bacterial pneumonia 
caused by infections such as Streptococcus pneumoniae, Staphylococcus aureus and 
Hemophilus influenzae [15].  
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1.6.2 Avian influenza 
H5N1 influenza infection in humans is still poorly understood. Current data has 
indicated that the incubation period for H5N1 may be longer than seasonal influenza, 
from two to eight days and possibly as long as 17 days. Currently, WHO has 
recommended an incubation period of seven days. Initial symptoms of H5N1 influenza 
are similar to influenza-like symptoms, but exceptions have been reported in some 
patients such as diarrhoea, vomiting, chest pain, abdominal pain, and bleeding from the 
nose and gums. Another symptom that appears to be more common in H5N1 influenza 
than in seasonal influenza is watery diarrhoea without blood. The development of 
manifestations in the lower respiratory tract is observed in many patients early in illness. 
Other symptoms that are commonly seen in patients are respiratory distress, hoarse 
voice, and crackling sound when inhaling [3]. The patients infected by H5N1 virus often 
are subjected to a very aggressive clinical course. They often develop primary viral 
pneumonia and multi-organ failure. The disease is characterized by rapid deterioration 
and high fatality [35].  
 
1.6.3 Novel influenza A (H1N1) virus 
Recently a novel influenza A/(H1N1) virus has infected humans and has caused a 
serious influenza outbreak. By 29th of June 2009 more than 70893 infected cases (of 
these 311 deaths) distributed in 115 countries have been officially reported [48]. The 
influenza A/(H1N1) virus is new, and it has not been found in pigs or humans before. 
The influenza A/(H1N1) viruses that have been characterized so far, have showed to be 
sensitive to oseltamivir, but resistant to amantadine and rimantadine [49]. The WHO 
raised the current level of influenza pandemic alert to phase 6 [50], declaring the start of 
a new pandemic. 
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1.7 The immune response to influenza 
 
1.7.1 Innate immune response 
The early line of defence against pathogens is provided by the innate immunity (also 
known as natural or native immunity). The innate immune system serves two important 
functions. It initiates the response to microbes that may prevent, control, or eliminate 
infection of the host. It stimulates as well the adaptive immune response to pathogens 
(i.e. influenza). The innate immune response does not have the ability to “remember” 
upon repeated exposure to an antigen and is non-specific [31]. 
 
1.7.2 Adaptive immune response  
In contrast to innate immunity, adaptive immunity is antigen-specific and is capable of 
recognizing and providing a more rapid and vigorous response to repeated exposures of 
the same microbe. Adaptive immunity consists of two types, humoral and cell-mediated 
immune responses. The first is mediated by antibodies produced by B cells, which is 
required for the neutralization of the influenza virus and therefore for the prevention of 
clinical influenza infection [86]. The latter is characterized by activation of T cells. 
Recovery from infection is mediated by cytotoxic T cells that induce lysis of influenza 
infected cells [36]. There is a connection between these two arms of adaptive immune 
system, which is essential to mount an effective immune response, see fig. 1.7.  
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7A schematic overview of the adaptive immune response to influenza virus. The scheme 
describes the interactions between the different cell types that are involved in the immune response. 
Abbreviations: ADCC: antibody-dependent cell-mediated cytotoxicity, Ag: Antigen, APC: Antigen 
presenting cell, CD: Cluster of differentiation, CTL: Cytotoxic T lymphocyte, DC: dentritic cell, Ig: 
Immunoglobulin, IFN: Interferon, IL: Interleukin, MHC: Major histocompatability complex, Tc: cytotoxic 
T cell, TCR: T cell receptor, TGF-β: Transforming growth factor, Th: T helper cell, Thp: T helper 
precursor. Kindly provided by Dr. Abdullah Madhun. 
 
 
1.7.2.1 Cell-mediated immune response  
Cell-mediated immunity consists mainly of two components, CD4+ and CD8+ T cells. 
The former, also called T helper (Th) cell, secrete different cytokines which play the key 
role in the regulation of the humoral and cellular immune response [28]. While CD8+ 
cells mediate cytotoxic responses. 
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1.7.2.1.1 CD4+ T cell 
CD4+ T cells can differentiate into subsets of effector cells, Th1, Th2, and Th17 cells. 
The characteristics of these subsets are based on how they are induced, which cytokines 
they secrete and their effector mechanisms. Induction of Th cells requires antigen 
presentation via class II major histocompatability complex (MHC) molecule by dentritic 
cells (DCs) or macrophages. In addition, the type of cytokines that are secreted by DCs 
determine the Th polarization of the immune response to Th1 or Th2 dominance. 
Differentiation of the Th precursor to the Th1 subsets is promoted by IL-12 that is 
secreted by DC, while IL-4 induces the differentiation of Th precursor to Th2 subsets 
(reviewed in [33]). Cytokines (IFN-γ and IL-2) that are secreted by Th1 cells, are 
necessary for the development of cell-mediated immunity. Additional, IFN-γ cytokine 
induces the isotype-switch in B cells to IgG2a antibody and both are therefore used as a 
marker of a Th1 response [25]. Conversely, differentiation and proliferation of B cells 
and isotype-switching of antibodies (IgE, IgG1 and IgA) are stimulated by Th2 
cytokines (IL-4, IL-5, and IL-10), which are important in the humoral immune response 
[24, 25]. Th2 cytokines and IgG1 antibody are used as indicators of the Th2 profile. The 
cytokines produced by Th cell subsets result in the development and expansion of their 
respective subsets. Therefore, cytokines secreted by one subset promotes further 
differentiation of that subset and inhibits the proliferation of the other subset [81].  
Th17 cell is classified as the third subset of differentiated effector CD4+T cells in mice. 
These cells secrete the pro-inflamatory cytokine, IL-17, and is involved in the promotion 
of dentritic cell and neutrophil maturation, which are important in the contribution of the 
protection against bacteria and fungi [82]. Differentiation of Th17 cell is inhibited in the 
presence of IFN-γ and IL-4 [34].  
 
1.7.2.1.2 CD8+ T cell 
Differentiation of naïve CD8+ T cells into cytotoxic T lymphocytes (CTLs) require 
antigen recognition that is displayed by class I MHC molecules on the surface of the 
infected cell and stimulation by Th1 cytokines. The CTL´s antigen receptor must 
recognize peptide-MHC class I on the infected cell before the CTLs kill the infected cell 
by two main mechanisms. Firstly, CTLs release complexes of perforin and granzymes 
that enter the infected cell. The granzymes penetrate into the cytoplasm of the infected 
cell and induce apoptosis [77]. Secondly, FasL receptor that is expressed on CTLs, 
engages with Fas receptor on the surface of infected cells, and induces apoptosis [34]. 
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The memory cells of both CD4+ and CD8+ cells can reactivate and give a rise to a more 
rapid immune response if the same antigen is re-encountered. The CTLs provide broad 
cross-reactivity against drifted influenza strains because they recognize the internal viral 
proteins, which are highly conserved among influenza viruses [89]. 
 
1.7.2.2 The humoral immune response  
The initiations of humoral immune response occur by the recognition of antigens by B 
cells. Membrane immunoglobulin M (IgM) and IgD receptors on naïve B cells bind to 
antigens. When this occurs together with the essential stimulations by Th cells, the B 
cells become activated. Activated B cells undergo clonal expansion (proliferation; 
expansion of the clone of antigen-specific lymphocytes) and differentiate into antibody-
secreting plasma cells, memory cells and progeny of clones that produce other Ig 
isotypes (e.g., IgG or IgA). Some plasma cells migrate to the bone marrow where they 
live for many years and continue to produce low levels of antibodies for long periods, 
which provide long-lasting antibody-mediated immunity. Memory cells play an 
important role in the secondary antibody responses by mount rapid responses after re-
encounter with the same antigen [17]. Progenies of clones that produce other Ig isotypes 
(isotype-switching) are determined by cytokines, which are secreted by helper T cells 
and this process is essential for the development of the humoral response. IgG 
antibodies serve three different effector functions [52]: 1) opsonization of antigens that 
leads to phagocytosis by neutrophils and macrophages, 2) antibody-dependent cell-
mediated cytotoxicity which is mediated by natural killer cells, and 3) activation of the 
classical pathway of complement. 
 
1.7.2.3 Mucosal immunity 
The mucosal immune system serves as the first line of defense against influenza virus 
that enters into humans, via mucosal surfaces. The mucosal arm of immunity is 
mediated by dimeric IgA (dIgA) antibody. DIgA is a composition of two IgA molecules 
held together at the end of the Fc region by J-chain. The poly-Ig receptor on the surface 
of the mucosal epithelial cell recognizes the J-chain and transfers the dIgA to the lumen, 
which is termed secretory IgA (sIgA) [9]. The protection against influenza virus in the 
mucosal surfaces of the upper respiratory tract is mediated by sIgA, which neutralizes 
the virus by forming an antigen-antibody complex that blocks the receptor-binding site 
on HA without causing tissue damage. Another antibody class that contributes to this 
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neutralization is IgG, which transudes to the mucus by diffusion. The sIgA antibodies 
have broader cross-reactivity than IgG and therefore provide protection against drifted 
viruses. In the infected epithelial cell, dIgA antibodies that are crossing through the cell 
may bind to the newly synthesized viral proteins and inhibit the viral assembly process. 
The lung parenchyma lacks sIgA system, therefore the protection against influenza 
pneumonia is dependent mainly on serum-derived IgG [85].  
 
1.8 Vaccination 
A vaccine is a biological preparation that induces protective immunity against microbial 
diseases. To date, influenza vaccination remains the primary method for the prevention 
of influenza and the severe complications related to the disease. There are a multiple 
parameters that contribute to the variation of the efficacy of influenza vaccination, e.g. 
the route of vaccination, the type of vaccine, the immunologic status, the age of the 
recipient, and the match of vaccine to the circulating strain [21]. The primed individuals 
that were vaccinated parenterally with killed virus provide a rapid systemic immune 
response in the blood and a poor immune response at mucosal sites. In order to induce a 
stronger mucosal immune response, the vaccine can be administered intranasally [13]. 
Intranasal vaccination strategy does not only prevent the disease but also blocks early 
infection. The horizontal transmission to susceptible hosts is thus reduced. There are 
other benefits that are associated to this mucosal vaccination. It is easy to administer. It 
does not have to be administered by qualified health personal. It is widely accepted by 
the public. However, intranasal vaccination of antigen alone is poorly immunogenic. 
Therefore, mucosal adjuvant can be utilized to overcome this problem [44]. To date, the 
market has no vaccine formulation containing mucosal adjuvant approved for human 
use, which highlights the urgent need of effective mucosal adjuvants. In the face of most 
infections, induction of both mucosal and systemic responses after vaccinations is 
important [53].  
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1.8.1 Inactivated vaccines 
Inactivated vaccines consist of three main formulations, e.g. whole virus, split virus and 
subunit vaccine. Inactivation of whole virus vaccine is performed by using chemical 
agents (e.g. formalin, β-propiolacetone, or heat) [14]. Inactivated whole virus vaccine is 
no longer in use due to the increased risk of side reactions. Split virus vaccine is 
prepared by disruption of the viral membrane by using other chemical agents (e.g. ether) 
[54]. Previous studies have reported that split virus vaccine is less immunogenic but had 
less side-effect than the whole virus vaccine [14, 55]. The subunit vaccine used in 
current study was composed of antigens (HA and NA surface proteins) purified from the 
influenza viruses (A/Vietnam/1194/2004) and administered with an adjuvant (described 
below).  
 
1.8.2 Adjuvant 
The function of an adjuvant is to stimulate the 
immune response without having any specific 
antigenic effect in itself. Adjuvant is a substance 
which enhances T cell activation by promoting 
the accumulation and activation of antigen 
presenting cells (APCs) at a site of antigen 
exposure [43]. There are other adjuvants that 
have different properties, e.g. aluminium containing, cholera toxin (CT), heat-labile 
toxin (LT of E. coli) and CpG (dinucleotides) adjuvants. Aluminium containing 
adjuvants induce primarily the humoral immune response [57]. Their mechanism of 
action is considered to be divided into three parts: 1) involving delayed clearance of the 
antigen from the injection site [58], 2) stimulating the recruitment and activation of 
APCs by induction of local inflammatory tissue [59], and 3) facilitating antigen uptake 
by phagocytosis in APCs by conversion of soluble antigens into a particulate form [60]. 
CT and LT adjuvant have similar structure to one another and are an ADP-ribosylating 
enterotoxins that can cause diarrhea. Using CT or LT as a mucosal adjuvant can result in 
enhancement of antigen-specific secretory and systemic antibody responses, and 
amplification of cellular immunity [61, 62]. CpG dinucleotides consist of cytosine and 
guanine nucleotide that are connected by a phosphate and are present in the 
Figure 1.8 Molecular structure of  
c-di-GMP [47].  
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prokaryotes’s genome [64, 65]. During an infection, the CpG acts as a danger signal to 
the innate immune system and triggers strong immune response [63].  
 
The selected adjuvant in this research is an autoinducer bis(3’,5’)-cyclic dimeric GMP 
(c-di-GMP), which is represented as one of the cell-to-cell signalling systems in bacteria 
[66]. The molecule structure of c-di-GMP is shown in figure 1.8. Experiments have 
shown that increased levels of c-di-GMP correlate with increased bacterial aggregation 
and biofilm formation [67, 68]. Karaolis et al. have shown that c-di-GMP can act as a 
danger signal on eukaryotes and it stimulates the expression costimulatory molecules 
and cytokines by dentritic cells in humans [69, 70]. C-di-GMP has shown in mice to 
have immunomodulator effect that stimulates the immune system in the prevention of 
lethal bacterial infections (e.g. S. aureus) [70]. Increased survival rates and reduction in 
bacterial counts in lung and blood were observed when the mice are administered c-di-
GMP intranasally and subcutaneously before an intratracheal challenge with Klebsiella 
pneumonia [72]. More recently, research conducted by Ebensen et al. have shown that 
intranasal [44] and subcutaneous [71] vaccinations of mice with β-galactosidase 
adjuvanted with c-di-GMP induced strong humoral and cellular immune responses with 
balanced Th1/Th2 profile. Thus, c-di-GMP is a promising adjuvant for development of 
intranasal pandemic influenza vaccines. 
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1.9 Aim of the study 
 
In recent years, the world has been threatened by a high pathogenic H5N1 virus, which 
has the potential to cause a pandemic. This influenza virus has a mortality rate 
approximately 60 % but, fortunately, it has not evolved the ability to transmit from 
human to human. Thus, it is necessary to have a good vaccine available if this virus 
evolves further.  
Previous reports have shown that paranteral vaccination induces rapid systemic immune 
response, but poor mucosal immune response. In contrast, an effective intranasal 
vaccine may induce local immune response which blocks influenza virus at the entry 
site and reduces further transmission. Intranasal vaccination of influenza antigen alone is 
poorly immunogenican effective and safe mucosal adjuvants are needed. Studies by 
Ebensen et al. [44] have shown promising results for the mucosal adjuvant c-di-GMP. 
Intranasal vaccine that induces a rapid stimulation of both mucosal and systemic 
immune responses will provide an important measure in combating influenza pandemic.  
 
The aim of this study was to investigate and compare the mucosal, humoral and 
cytokine immune responses induced in mice after intranasally vaccination with 
influenza A(H5N1) subunit vaccine adjuvanted with c-di-GMP and non-adjuvanted 
subunit vaccine.  
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2. Materials 
 
2.1 Animals 
Name             Supplier 
BALB/c mice, female Taconic M&B A/S, Denmark 
 
 
2.2 Vaccine             
Name            Supplier 
Concentrated Subunit NIBRG-14 
vaccine (A/Vietnam/1194/2004) 
Archimedes Development Ltd,  
United Kingdom 
 
 
2.3 Antigen 
Name             Supplier 
Whole virus, NIBRG-14 Archimedes Development Ltd,  
United Kingdom 
 
 
2.4 Anesthesia 
Name          Cat. no             Supplier 
Rompun vet (20 mg/ml) 023446 Bayer, Germany 
Ketalar (50 mg/ml) 150086 Pfizer, USA 
 
 
2.5 Antibodies 
2.5.1 Capture antibody   Cat. no   Supplier 
Goat anti-mouse IgA 1040-01 
Goat anti-mouse IgG 1030-01 
Goat anti-mouse IgG1 1070-01 
Goat anti-mouse IgG2a 1080-01 
Goat anti-mouse IgM 1020-01 
Southern 
Biotechnology, USA 
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2.5.2 Immunoglobulin standards  Cat. no   Supplier 
Mouse IgA (1 mg/ml) M1421 
Mouse IgG  (1 mg/ml) I5381 Sigma, USA 
Mouse IgG1 (0,5 mg/ml) 0102-14 Southern 
Biotechnology, USA 
Mouse IgG2a (1mg/ml) M9144 
Mouse IgM (1 mg/ml) M3795 Sigma, USA 
 
 
 
2.5.3 Biotin antibody   Cat. no   Supplier 
Biotin-anti-mouse IgA  1040-08 
Biotin-anti-mouse IgG 1030-08 
Biotin-anti-mouse IgG1 1070-08 
Biotin-anti-mouse IgG2a 1080-08 
Biotin-anti-mouse IgM 1020-08 
Southern 
Biotechnology, USA 
 
 
2.6 Kits  
Name      Cat. no    Supplier 
Mouse Cytokine Grp I X-Plex 
Assay  
(Cytokine 6-plex – IL-2, IL-4, 
IL-5, IL-10, IL-17, IFN-γ) 
X6000006RJ 
Bio-plex Reagent Kit 171-304000 
Bio-plex Calibration Kit 171-203060 
Bio-Rad Laboratories, 
USA 
 
 
2.7 Plates 
Name      Cat. no    Supplier 
Greiner Microplatte (ELISA) 6500, F Greiner, Germany 
Multiscreen HTS, BV (Bio-plex) MSBVN1250 Millipore, United 
Kingdom 
96 V-well polystyrene microwell 
plates (HI) 
249570 Nunc, Denmark 
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2.8 Reagents 
Name     Cat. no   Supplier 
Citric acid monohydrate 
(C6H8O7·H2O) 
1.00242 Merck, Germany 
Con A (Concanavalin) C5275 Sigma, USA 
Di-Sodium hydrogen phosphate 
anhydrous (Na2HPO4) 
1.06586.2500 Merck, Germany 
DMF (dimethylformamide) 10322 BHD AnalaR, England 
Extravidin Peroxidase Conjugate  E-2886 Sigma, USA 
FBS (foetal bovine serum) 14-710F BioWhittaker, 
Belgium   
Glacial acetic acid (CH3CO2H) 1.00063.1000 Merck, Germany 
Hydrogen peroxide 30 % (H2O2)  H-1009 Sigma, USA 
Lymphoprep  1001967 Nycomed Pharma AS, 
Norway 
NCS (Newborn Calf Serum) ECS0070L Euroclone 
OPD (o-Phenylenediamine)  
(10 mg tablets) 
P-8287 Sigma, USA 
Potassium dihydrogen phosphate 
(KH2PO4) 
1.04873 Merck, Germany 
PSF 
(penicillin/streptomycin/fungizon
e) 
17-745E BioWhittaker, 
Belgium   
RPMI 1640 + L-Glutamine 21875-034 Gibco, UK 
Trypan blue stain (0,4 %) 17-942E BioWhittaker, 
Belgium   
RDE  Denka Seiken, Tokyo, 
Japan 
Turkey blood 07801 The National Institute 
for Biological 
Standards and Control, 
United Kingdom 
Tween 20 
(polyoxyethylene sorbitan 
monoaurate) 
P-1379 Sigma, USA 
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2.9 Solutions and buffers 
 
2.9.1 ELISA solutions 
Name      Description 
Citric acid 
(0,1M C6H8O7) 
- 11,4 g C6H8O7 
- 500 ml ddH2O 
Dibasic sodium phosphate  
(0,2M Na2HPO4) 
- 14,2 g Na2HPO4 
- 500 ml ddH2O 
Phosphate citrate buffer 
(pH 5,0) 
- 257 ml 0,2M NaHPO4 
- 243 ml 0,1M C6H8O7 
- 500 ml ddH2O 
OPD solution 
(Ortho-phenyldiamine 
dihydrochlorid) 
- 10 mg OPD (tablet) 
- 25 ml Phosphate citrate buffer 
Sulphuric acid  
(1M H2SO4) 
- 70 ml 98 % H2SO4 
- 430 ml ddH2O 
 
 
 
2.9.2 Buffers and medium   
Name      Description  
Lymphocyte medium (LM) - 86 ml RPMI 1640 medium supplemented  
  L-glutamine 
- 1 ml 100x non essential amino acids 
- 1 ml 1 M Hepes pH 7.4 
- 1 ml PSF 
- 10 ml heat-inactivated FBS 
PBS (10x) 
(Phosphate Buffered Saline) 
(pH 7,2) 
- 400 g NaCl 
- 10 g KCl 
- 72 g Na2HPO4 
- 12 g KH2HPO4 
ddH2O ad 5 L 
PBS/FBS 
(PBS containing 10 % FBS) 
- 90 ml PBS 
- 10 ml FBS 
PBS/NCS 
(PBS containing 20 % NCS) 
- 80 ml PBS 
- 20 ml NCS 
PBS/T 
(PBS containing 0,05 % Tween) 
- 500 ml  
- 4500 ml dH2O 
- 2,5 ml Tween 20 
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3. Methods  
 
3.1 Experimental protocol 
 
3.1.1 Mice 
In the current study, fifty five BALB/c mice (6-8 week old, female) were used which 
was approved by “Forsøksdyrutvalg” and conducted according to the Norwegian 
Animal Welfare Act. All animals used were housed in a specific pathogen free, 
temperature 21˚C with 12 hour light/dark cycles and food and water ad libitum at the 
animal housing facility (Vivarium), at the University of Bergen.  
 
3.1.2 Immunization 
Forty mice were randomly divided into two equal groups, where one group was 
vaccinated intranasally with 15 µg of A/Vietnam/1194/2004 (H5N1) subunit vaccine 
adjuvanted with 5 µg c-di-GMP, whilst a second group was immunized with subunit 
vaccine alone. In addition, fifteen mice received only PBS which served as a control 
group.  
 
Intranasal vaccination of mice was performed as follows. Mice were primary 
anaesthetized and laid on their back before the required volume of vaccine was given in 
droplet into the nostrils. The total vaccine volume was divided into two portions for 
each nostril cavity. To ensure that the vaccine was only administered intranasally a 
maximum volume of 5.5 µl per nostril was administered. The adjuvanted vaccine was 
administered 4.5 µl per nostril 3 times and the non adjuvanted vaccine 5.5 per nostril 
twice.  
 
3.1.3 Sacrifice 
The mice were individually placed in a chamber and carbon dioxide (CO2) was used as 
an asphyxiant for euthanasia.  
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3.2 Sampling and spleen collection 
 
Weekly blood samples could not be collected from the mice because of their size. To 
obtain a total overview of the kinetics of the immune response, each group was divided 
into four subgroups, with samples collected as shown in the experimental outline (fig. 
3.1).   
 
 
 
Fig. 3.1 The experimental outline. Mice were vaccinated intranasally with two doses at three weeks 
interval with either the subunit vaccine with adjuvant or alone. Peripheral blood and nasal washes was 
collected on blood sampling days (blue font). Cardiac blood, nasal washes and the spleen were collected 
on the day of sacrifice (green font).  
 
3.2.1 Collection of nasal wash (NW) samples 
The mouse was restrained by holding the scruff of the 
neck and the tail. Sterile PBS/BSA (0.35 ml) was 
flushed in large droplets into the mouth and out through 
the nose and collected in a petri dish (fig. 3.2). Each 
sample was collected in a separately labelled eppendorf 
tube and immediately placed on ice. The NWs were 
then stored at -80 ˚C until processing.  
 
 
 
 
 
Figure 3. 2 Collection of NW 
samples. 
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3.2.2 Peripheral blood sampling 
The mouse was placed in a tube and the hind leg was 
exposed by holding the skin between the tail and 
thigh. The fur on the leg was shaved using a scalp 
blade (fig. 3.3) and a 23 gauge needle was used to 
puncture the saphenous vein. A labelled microvette 
was used to collect the venous blood (50-100 µl). 
After the blood was taken, pressure was applied to the 
vein to stop the blood flow. 
 
3.2.3 Cardiac blood sampling (sacrifice) 
Cardiac blood samplings were only collected on the 
sacrifice days. After euthanasia, the mouse was 
pinned to a dissection plate and the chest was opened 
(from the throat to the abdomen). Blood was collected 
directly from the heart by cardiac puncture using a 23 
g needle with a 2 ml syringe (fig. 3.4). The blood was 
collected in a labelled eppendorf tube. 
 
3.2.4 Separation of sera 
The blood was allowed to clot at room temperature for approximately five hours. The 
clotted blood was then centrifuged for 10 minutes at 1000 g before the serum was 
transferred to a new microtube and stored at -80 ˚C until tested by ELISA and HI assays. 
 
3.2.5 Spleen collection (sacrifice) 
The spleen was removed aseptically from dissected mice and transferred to a tube 
containing 3 ml of sterile PBS. The tissues were kept cold until further processing.  
 
 
 
 
 
 
Figure 3.3 The saphenous vein, where 
the peripheral blood was taken. 
Figure 3.4 The cardiac blood sampling. 
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3.2.6 Isolation of lymphocytes from spleen 
The spleen was placed in a sterile petri dish and punctured with a 23 gauge needle. The 
spleen cells were washed out of the spleen with 3 ml PBS/FBS into the petri dish. 
Afterwards, the cells were collected in a 15 ml tube. The wash procedure was repeated 
with a new 3 ml PBS/FBS medium to achieve a total volume of 6 ml cell suspension. 
The spleen was flushed until all cells were removed from the spleen when its colour 
turned greyish. The procedure was performed in a LAF-bench at room temperature. 
 
The 6 ml cell suspension was carefully laid onto 3 ml of Lymphoprep in a 15 ml 
centrifuge tube. The tube was centrifuged at 800 g for 30 minutes at room temperature 
with no brake. The distinct band containing the lymphocytes was carefully removed 
using a pasteur pipette and transferred to a new 15 ml centrifuge tube. Cold PBS/FBS 
medium was added to make a total volume of 8 ml. The lymphocytes were washed twice 
with 8 ml of PBS/FBS by centrifuging at 250 g for 10 minutes at 4 ˚C. The spleen cells 
were re-suspended in lymphocyte medium (LM) to a final volume of 2 ml. The isolated 
lymphocytes were counted by trypan blue exclusion (0.4 %) using flow cytometry. The 
concentrations of lymphocytes were adjusted in LM to 1.0 x 107 cells/ml and 
immediately activated in vitro. 
 
3.3 Immunological Assays  
 
3.3.1 In vitro activation of lymphocytes 
One hundred micro litres of isolated splenic lymphocytes (1.0 x 106 cells) and one 
hundred micro litres of appropriate activation medium were added into 96-wells flat 
bottom tissue culture plates and incubated for 72 hours at 37 ˚C in a humidified 
atmosphere of 5 % CO2. Two different mediums were utilized to activate the 
lymphocytes; (1) influenza (H5 virosomal antigen) activation medium containing 10 µg 
HA/ml or (2) a mitogen (PMA) activation medium containing 10 µg PMA/ml. The latter 
was used as a positive control. Cells with only LM were used as negative control. After 
incubation, the content of the wells were transferred to a V well bottom plate and 
centrifuged at 300 g for 10 minutes. The supernatants were transferred to a new plate 
and stored at -80 ˚C until analysed in Bio-plex bead immunoassay.  
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3.3.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
The 96-well ELISA plates were coated with 100 µl/well of 2 µg/ml whole influenza, 
A/Vietnam/1194/2004(H5N1), or with 1/1000 dilution of goat anti-mouse capture 
antibody (IgA, IgG, IgG1 or IgG2a) in PBS overnight at 4 ˚C. The plates were blocked 
with 200 µl/well PBS/NCS (20 %) for 1 hour at room temperature. Mouse NW was 
diluted in two-fold dilutions, ranging from 1:5 and 1:10. Five folds dilution, 1/50 and 
1/250 dilutions were prepared for mouse sera. Mouse antibody standard was diluted in 
two-fold dilutions, starting from 50 ng/ml to 0.781 ng/ml and each dilution in duplicates 
was added to each plate. The diluted sample and antibody standard were added (100 
µl/well) to the appropriate wells in duplicate. After 2 hours incubation for NW samples 
or 1.5 hour sera at room temperature, the plates were washed 6 times with PBS/T (0.05 
%) using Nunc Elisa washer. Goat anti-mouse antibody specific-biotinylated conjugate 
diluted in PBS/NCS (1/500) were added 100 µl/well and incubated for 1 hour at room 
temperature. The plates were washed 6 times with PBS/T and incubated for an 
additional hour 100 µl/well of extravidin peroxidase diluted 1:1000 in PBS/NCS (20 %). 
The plates were washed 6 times with PBS/T, prior to addition of the substrate 100 
µl/well (10 mg OPD, 25 ml 0.05 phosphate citrate buffer pH 5, 20 µl H2O2) for 
development.  After incubating the plates for 10 minutes in the dark, the reaction was 
stopped with 100 µl/well of 1M H2SO4. The Labsystem Multiscan reader was used to 
read the optical densities of the wells (OD) at 492 nm. The influenza specific antibody 
concentrations were calculated in µg/ml using standard curves plotted as log-log graphs 
in the Ascent program (Ascent Software Version 2.6).  
 
 
3.3.3 Haemagglutinin inhibition assay (HI assay) 
 
3.3.3.1 Preparation of turkey red blood cells  
The turkey blood was centrifuged in 250 g for 10 minutes at 4 ˚C. The supernatant was 
removed before 4 ml of sterile PBS was added and centrifuged as described above. This 
procedure was repeated until supernatant was clear (no haemolysed red blood cells). The 
turkey blood cells diluted in 0.7 % (v/v) in PBS for use in the virus titration and HI 
assays.  
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3.3.3.2 Treatment of sera 
To remove non-specific inhibitors in the serum, 240 µl RDE (reconstituted in PBS) was 
added to 60 µl sera (volume 5:1) and incubated at 37 ˚C overnight. The remaining RDE 
was heat-inactivated by incubation of the treated serum at 56 ˚C for 30 minutes. The 
serum was allowed to cool to room temperature.  
 
 
3.3.3.3 Virus titration 
This procedure is used to determine the amount of influenza virus and therefore is 
necessary for standardising the amount of virus in the HI assay.  
Fifty micro litres of PBS were added to each well in a V-bottomed microtiter plate. Then 
50 µl of virus suspension was added to the first row and mixed and a 2-fold dilution 
series was made the rest of the rows. The last 50 µl was discarded. Control wells 
contained no virus. 50 µl/well of 0.7 % red blood cells was added to each well and 
incubated at room temperature for 30 minutes. The plates were read by tilting, which 
allowed the non-agglutinated red blood cells to run downwards. HA titres were 
calculated as the reciprocal of the dilution of virus giving 50 % haemagglutination. The 
virus titre was adjusted to be 8 HA units (HAU)/50 µl. 
 
 
3.3.3.4 HI assay 
The HI assay was run in a 96-wells V-bottomed microtiter plate. A two fold dilution of 
RDE treated sera (from an initial of 1/8 dilution) were made in PBS giving a final 
volume of 50 µl, as described under virus titration. Fifty micro litres of the standardized 
virus (8 HAU/50 µl) was added to each well and incubated at room temperature for 1 
hour. Then 50 µl of 0.7 % of turkey red blood cells were added to each well and 
incubated at room temperature for 30 minutes. The haemagglutination inhibition titre 
was read by tilting the plates, which allowed the nonagglutinated red blood cells to run. 
The HI titre was calculated as the reciprocal of the highest dilution of serum needed to 
inhibit 50 % haemagglutination.  
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3.3.4 Bio-plex bead immunoassay 
The bio-plex bead immunoassay was performed according to the manufacturer’s 
protocol.  
The wells of the supplied plates were pre-wet with 100 µl of assay buffer A before 25 µl 
of vortexed-bead suspension was added. The beads were washed twice with 100 µl of 
Working Wash Solution. Standards were prepared according to the manufactures 
instruction and added to the appropriate wells. 25 µl/well of supernatant from in vitro 
activated cells and 25 µl/well assay diluents (LM) were added to the remaining wells. 
The plate was sealed and incubated on an orbital shaker (Heidolph titramax 100) at 
room temperature for 30 seconds at 1,100 rpm, then for 45 minutes at 300 rpm. The 
liquid was removed by washing three times with 100 µl of Working Wash Solution. 
Biotinylated detector antibody (biotin: anti IFN-γ, IL-2, IL-4, IL-5, IL-10 and IL-17) 
was added to each well (25 µl/well) and incubated at room temperature on an orbital 
shaker for 30 seconds at 1,100 rpm, then for 30 at 300 rpm. The plate was washed three 
times with 100 µl Working Wash Solution before 25 µl of Vortex Streptavidin-PE was 
added and incubated at room temperature on the orbital shaker (30 seconds at 1,100 rpm 
subsequently 10 minutes at 300 rpm). Then the plate was washed three times more with 
100 µl PBS/T before assay buffer (100 µl/well) was added to each well and the plate 
was put on the orbital shaker for 30 seconds at 1,100 rpm. The plate was analysed in the 
Luminex 100TM instrument and the concentration of the cytokines were calculated using 
standard curves by Bioplex manager 5.0. 
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3.4 Statistical analysis 
The following formulas were used to calculate the results (statistic value) of the 
experiment: 
 
Mean      
 
 
Standard deviation    
   
 
Standard error of the mean    
 
 
Geometric mean    
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4. Results 
In the current study, we have investigated the local and systemic immune responses 
elicited in mice after intranasal vaccinations with influenza A H5N1 vaccine. The 
animals were randomly divided into two groups of 20 mice each on the basis of the 
vaccine formulations: subunit vaccine adjuvanted with c-di-GMP or subunit vaccine 
alone. Additionally, 15 mice were used as a control group (vaccinated with PBS). The 
experimental design (immunization and sampling days) is described in Methods (section 
3). 
There were no detectable influenza-specific immune response in control animals and 
therefore, the results are not presented.  
 
4.1 The antibody response after the intranasal vaccinations 
A number of immunological assays were used to analyse the influenza specific 
response. ELISA assay was used to quantify the influenza specific antibodies in the 
serum (IgG, IgG1, IgG2a, and IgA) and NW (IgA), before and after influenza 
vaccination. The haemagglutinin inhibition (HI) assay was conducted to measure the 
titre of anti-HA antibodies elicited after vaccination.  
 
 
4.1.1 The influenza-specific antibody response quantified by ELISA 
assays 
 
Figure 4.1 Serum influenza-specific IgG concentrations after the first vaccination (A) and the second 
vaccination (B). The IgG concentrations after vaccinations with 15 µg HA with c-di-GMP adjuvant 
(blue) or alone (purple) at various sampling intervals. The results are represented as the mean 
concentration (µg/ml) of 5 mice ± SEM. Differences were statistically significant at a P value of <0.05 (*) 
when compared with the mice vaccinated with subunit alone.  
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One week after the first immunization (fig. 4.1 A), low concentrations of IgG (0.2 
µg/ml) were detected in the group that received subunit antigen adjuvanted with c-di-
GMP. The IgG concentration continued to increase, with concentrations of 1 µg/ml and 
4 µg/ml observed at the second and the third week after vaccination. On the other hand, 
no or very low IgG concentrations (0.1 µg/ml after the second week) were detected in 
the mice immunized with subunit alone, although an increase (0.9 µg/ml) was observed 
in the third week. However, the IgG level was more than 7-fold (second week) and 4-
fold (third week) higher in the group that was immunized with adjuvant vaccine 
compared to the group that received subunit vaccine alone.  
The IgG levels were boosted for both mouse groups after the second vaccination, but the 
highest concentrations were observed in the mouse group immunized using cdiGMP as a 
mucosal adjuvant (fig. 4.1 B). The level of IgG significantly increased (approximately 
20-fold) four days after the second vaccination (fig. 4.1 B) compared the group 
immunized with subunit alone (approximately 5-fold). For both groups, the IgG levels 
peaked one week after the second vaccination, although significantly higher (44-fold 
higher) levels were observed in the group receiving subunit with c-di-GMP (603 µg/ml), 
than the group receiving the vaccine without adjuvant (14 µg/ml). The IgG levels 
declined in the following sampling points in both groups although the group with 
adjuvant still had significantly higher IgG levels than the group without adjuvant. 
 
 
 
Figure 4.2 Ratio between IgG2a/IgG1 after vaccination of the groups. Serum samples were first 
analyzed at the third week after the first vaccination and at various time intervals after the second 
vaccination. The IgG2a/IgG1 ratios are calculated by dividing the IgG2a concentration with IgG1. A ratio 
over 1 is classified as Th1 biased profile, whereas less than 1 is characterized by a Th2 profile. The results 
of each group are presented as the ratio of 5 mice. 
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Due to the low IgG concentrations in sera at the first and second week after the first 
vaccination, the quantifications of IgG subclasses were not performed until the third 
week after the first dose. In the adjuvant group, IgG2a dominated the response 
throughout the study as shown by IgG2a/IgG1 ration (Fig. 4.2). On the other hand, the 
response in the non-adjuvanted vaccine group was not detected until one week after the 
second immunization and was mainly IgG1. 
 
 
 
Figure 4.3 Serum influenza-specific IgA concentrations after the first vaccination (A) and the second 
vaccination (B). The IgA concentrations after vaccination at various sampling intervals for the mouse 
group that received formulated vaccine with adjuvant (blue) and the mouse group that received subunit 
vaccine alone (purple). The results are represented as the mean concentration (µg//ml) of 5 mice ± SEM. 
Differences were statistically significant at a P value of <0.05 (*) when compared with the mice 
vaccinated with subunit alone. 
 
 
One dose of c-di-GMP adjuvanted vaccine elicited significantly higher serum IgA 
antibody levels than non-adjuvated vaccine (fig. 4.3 A), with the peak response 
observed three weeks after vaccination in both groups. The IgA antibody concentrations 
continued to increase up to three weeks post vaccination in the animal group that 
received antigen adjuvanted with c-di-GMP (245 ng/ml at the second week and 283 
ng/ml at the third week). In contrast, the group without adjuvant showed no increase in 
the IgA concentration until the third week post vaccination (42 ng/ml) (fig. 4.3 A).  
Four days after the booster vaccination (fig. 4.3 B), 18-fold increase in the IgA levels 
was observed in adjuvated vaccine group compared to the third week after the first dose. 
On the other hand, although the serum IgA concentration also increased in the non 
adjuvanted group (274.8 ng/ml), the increase was lower than in the adjuvanted group (7-
fold increase). In the group immunized with the adjuvant formulation, the IgA level 
peaked one week after the second vaccination with a concentration of approximately 
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54000 ng/ml and a significant decline was observed on the following sampling points. 
On the other hand, the peak IgA response after the second vaccination with the non-
adjuvanted vaccine was later at three weeks. C-di-GMP adjuvanted vaccine induced 
significantly higher IgA levels than non-adjuvanted vaccine through the study period. 
 
 
Figure 4.4 Nasal wash influenza-specific IgA after the first vaccination (A) and the second 
vaccination (B). IgA concentrations at various sampling intervals for the mouse group that received 15 
µg HA adjuvanted vaccine (blue) or vaccine alone (purple). The results are represented as the mean 
concentration (ng/ml) of 5 mice ± SEM. Differences were statistically significant at a P value of <0.05 (*) 
when compared with the mice vaccinated with subunit alone. 
 
 
One dose of intranasal immunization with adjuvant vaccine elicited a detectable IgA 
response in nasal wash as early as the first week, with the peak response observed in the 
third week (fig. 4.4 A). Very low concentrations (1 ng/ml) of IgA were detected after 
one dose of non-adjuvanted vaccine (fig. 4.4 A). After one vaccine dose, the IgA 
response was significantly higher in the c-di-GMP subunit vaccine group compare to 
subunit alone group. 
After the second vaccination, a small increase in the IgA level was observed for the 
group without adjuvant. In contrast, there was initially a sight decline in IgA 
concentration for the group with adjuvant (fig. 4.4 B). However, this group showed a 3-
fold increase one week (167 ng/ml) compared to 4 days (54 ng/ml) after the second 
vaccination. By the second week, both groups reached the peak with the adjuvant 
vaccine group having significantly higher IgA level (approximately 17 times) than the 
group without adjuvant. At weeks 3 and 10, IgA concentrations declined in both groups. 
Immunization with antigen formulated c-di-GMP induced significantly higher levels of 
NW IgA than antigen alone through the study. 
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4.1.2 Serum antibody response measured by HI assay 
The HI is a method for analyzing anti-HA response in serum and is commonly used for 
assessing the immunity after influenza vaccination. In human, a serum HI titre ≥ 40 
provide protection against seasonal influenza virus infection in 50 % of the population. 
 
 
 
Figure 4.5 The HI antibody response after vaccinations. The individual HI titres and the GMT of the 
group ± 95 % confidence interval at the various sacrificing weeks after one and two doses for the mouse 
group that received subunit vaccine added adjuvant (ovals) and the mouse group that received subunit 
vaccine alone (triangles). The results are represented as the geometric mean of 5 mice ± 95 % CI. 
 
 
After the first vaccination, no HI titers higher than the detection limit of the assay (HI 
titer =4) were observed in both groups (fig. 4.5). In the adjuvant group, GMT started to 
increase after the second vaccination, but an HI titers ≥ 40 were not detected until the 
third week after the second vaccination. A further increase in GMT (GMT >100) was 
noted 10 weeks after the second dose. None of the mice in the subunit alone group had 
an HI titer > 4 at any time point after the first and the second vaccination.  
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Figure 4.6 Concentration of cytokines in supernatants from in vitro activated splenic lymphocytes. 
The cytokines are separated based on their activity in the Th-profile immune response. (A) Th1-cytokines 
(IL-2 and IFN-γ), (B) Th2-cytokines (IL-4, IL-5 and IL-10), and (C) Th17 (IL-17) are shown for two 
groups of mice, those vaccinated with and those without adjuvant, three weeks after the second 
vaccination. It should be noted that there is a variation in the scale of the y-axis. The average 
concentration (pg/ml) of cytokine is shown from 5 mice per group ± SEM. Differences were statistically 
significant at a P value of <0.05 (*) when compared with the mice vaccinated with subunit alone. 
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4.2 The cytokine immune response  
Bio-plex bead immunoassay was conducted to determine the concentration of IFN-γ, IL-
2, IL-4, IL-5, IL-10 and IL-17 in supernatants from in vitro activated lymphocytes. IFN-
γ and IL-2 are regarded as indicators of a Th1 profile, whereas IL-4, IL-5, and IL-10 are 
considered as markers for a Th2 immune response. The Th17 response is characterised 
by the cytokine IL-17. 
 
The mouse group receiving the vaccine with adjuvant had a significantly higher Th1 
(IL-2 and IFN-γ) cytokines response compared to the group that did not received 
adjuvant (462-fold higher IL-2 and 34-fold higher IFN-γ) (fig. 4.6 A). However, higher 
concentrations of IL-4 and IL-5 were observed in the non adjuvanted group compared to 
the adjuvanted group. In contrast, the bio-plex bead immunoassay showed higher levels 
of IL-10 (approximately 4-fold) and of IL-17 (>100-fold higher) in the group with 
adjuvant compared to the non-adjuvanted vaccine group (fig. 4.6 B and fig. 4.6 C).  
 
4.3 Summary of the results 
 
After the first vaccination, the ELISA IgG and IgA concentrations in sera were low in 
the two vaccine groups. The IgA level in sera reached the peak at the first week after the 
second dose, in contrast to the IgA in nasal wash, which peaked two weeks after the 
second dose. An early booster effect (four days vaccination) was noticed in the group 
vaccinated with adjuvant and was reflected by high HI titres and high levels of serum 
antibodies. The IgG subclass distribution did not change after the second vaccination, 
with predominance of IgG2a in the group that was immunized with adjuvant and IgG1 
in the group without adjuvant. However, a significantly high IgG2a/IgG1 ratio in the 
group with adjuvant was detected at the second and third week after the second dose. 
The cytokine response was dominated by Th1 (IL-2 and IFN-γ) in the adjuvanted 
vaccine group, whilst by Th2 (IL-4 and IL-5) in the non-adjuvanted vaccine group.  
Furthermore, c-di-GMP adjuvanted vaccine induced higher levels of IL-10 and IL-17 
than non-adjuvanted vaccine group. 
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5. Discussion 
Influenza vaccination remains the primary method of prevention of influenza and the 
severe complications related to the disease. Influenza virus enters the host via the upper 
respiratory tract. Thus, an important area of research is the development of new 
influenza vaccines focusing on the induction of humoral and cellular immune responses 
at the both systemic and mucosal levels. Intranasal vaccination stimulates mucosal 
immune responses and prevents disease by blocking the virus at the site of entry to the 
host and preventing horizontal transmission. Subunit influenza vaccine is less 
immunogenic, but also less reactogenic than whole virus vaccine. Therefore, the use of 
adjuvant with subunit vaccine has the advantage of enhancing the immune response and 
overcoming the low immunogenicity. Ebensen et al. [44] have found intranasal 
vaccination with antigen formulated with c-di-GMP adjuvant, showed a significantly 
enhancement of IgG titre in sera, higher sIgA antibodies in the lung and a strong cellular 
immune response dominated by a Th1 response. Thus in the current murine study, this 
promising adjuvant was used to formulate an intranasal influenza A (H5N1) subunit 
vaccine. One mouse group was vaccinated intranasally with 15 µg of 
A/Vietnam/1194/2004 (H5N1) subunit vaccine with 5 µg mucosal adjuvant, c-di-GMP, 
while the other mouse group was immunized with the subunit vaccine alone.  
 
5.1 Formulation of subunit vaccine with c-di-GMP adjuvant induced a 
rapid humoral immune response.  
Virus neutralizing antibodies play a key role in resistance to infection and in the 
prevention of illness [86]. Induction of a high influenza-specific antibody level is 
desirable after vaccination, and for seasonal influenza strains an HI titre ≥40 correlates 
with protection [83]. In our study, higher serum IgG and IgA levels were observed after 
the first vaccination for the group immunized with c-di-GMP vaccine, indicating that the 
adjuvant induced a more rapid and stronger humoral immune response after one dose. 
Thus the use of adjuvant may reduce the time interval between vaccination and 
induction of protective immunity, which is of great importance in a pandemic scenario. 
A significantly higher serum antibody response was also observed after the booster 
dose, suggesting that this mucosal adjuvant further enhanced humoral immunity. 
Similarly, others have found higher IgG concentration after the first vaccination and 
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significantly higher levels after the booster dose in the mice immunized intranasally 
with β-Gal and c-di-GMP adjuvant compared to animals vaccinated with β-Gal alone 
[44].  
Furthermore, a significantly higher antibody response in mice vaccinated with adjuvant 
vaccine than in mice immunized with subunit alone was found by the tenth week. This 
suggests that mucosal adjuvant in the vaccine stimulated a long-lasting humoral 
immunity.  
 
The HI titre is a surrogate correlate of protection for seasonal influenza strains. We 
found that none of the vaccine formulations elicited HI titres after the first vaccination. 
Thus confirming in this murine model the need for two doses of influenza vaccine to 
mount a satisfactory antibody levels in naïve individuals [84]. However, as early as four 
days after the booster dose, the presence of the mucosal adjuvant in the vaccine 
enhanced the HI titer, which correlated with the increase of antibody levels in sera at the 
same time points (ELISA). An HI titre ≥40 was not detected until three weeks after the 
second dose and the GMT was over 100 by week 10, suggesting that two doses of 
subunit vaccine formulated with c-di-GMP adjuvant are required to obtain a sufficiently 
protective immune response in serum.  
Hagenaars et al. have shown that intranasal immunization with 5 µg subunit vaccine in 
female C57-BL/6 mice did not induce a detectable HI titer, which corresponded to no 
detectable influenza specific IgG concentration in sera [87]. In our study, a low HI titre 
in mice immunized with subunit alone also correlated with the low serum antibody 
levels measured by ELISA. These characteristics together may indicate that non-
adjuvanted subunit vaccine administered intranasally is poorly immunogenic.  
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5.2 The subunit vaccine with c-di-GMP adjuvant induced a 
more rapid and higher mucosal immune response than the 
subunit administered alone.  
Influenza viruses enter the body via the upper respiratory tract, where the mucosal 
immune system providing the first line of defence against infection. The mucosal arm of 
immunity is mediated by secretory IgA antibodies, which are the major neutralizing 
antibody against mucosal pathogens. However, sIgA antibodies do not only block 
influenza virus infecting mucosal epithelial, but also viral processes inside an epithelial 
cell [85]. Correlation of protection is less clear for mucosal antibodies [13]. The current 
study showed a detectable IgA response in the NW from mice immunized with c-di-
GMP adjuvanted vaccine as early as one week after the first vaccination. This antibody 
level increased strongly by the second week and was significantly higher at the third 
week compared to the non-adjuvanted vaccine group. A rapid mucosal response after 
just one intranasal vaccination can be a great advantage in a pandemic, because it can 
contribute to a rapid prevention of further transmission. After the booster dose, the IgA 
level in NW was significantly higher and peaked by the second week, and a long lasting 
local response was observed at 10 week post booster dose. This is one week later than in 
the IgA concentration in sera. A possible explanation can be that IgA antibodies 
antibody secreting cells circulate systematically before homing to mucosal sites.  
Only low IgA concentrations in NW were observed for the mouse group immunized 
with subunit vaccine alone [87]. Interestingly, low IgA levels were also observed in 
C57-BL/6 mice after intranasal vaccination with 5 µg subunit vaccine. Lethal challenge 
of these mice showed that only 1 of 5 mice survived but still had considerable weight 
lost.   
 
The findings supported by Asanuma et al. who have demonstrated that BALB/c mice 
intranasally vaccinated with 0.1 µg HA antigen combined with 0.1 µg cholera toxin B 
subunit (CBT) and 1 month later boosted with an increased dose (1.0 µg HA antigen 
adjuvanted with 0.1 µg CTB) induced high levels of HA-specific (IgA in NW and IgG 
in sera). In a protective efficacy study, no virus was detected in the upper (NW) or lower 
(lungs) respiratory tracts [95]. Interestingly, the mice immunized with mucosal adjuvant 
elicited also high IgA antibody level in NW and IgG antibody level in sera. This may be 
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a good reason to conduct a lethal challenge on the mice immunized with mucosal 
adjuvant to determine the productive efficacy. 
 
5.3 The presence of c-di-GMP in the formulation induced a Th1 biased 
profile. 
In mice, the T helper cell polarization after antigen exposure is indicated by the cytokine 
response and the IgG subclasses. High levels of INF-γ and IL-2 cytokines and IgG2a 
antibodies indicate a Th1 immune response, whereas high concentrations of IL-4, IL5 
and IL-10 cytokines and IgG1 antibodies are characterized as a Th2 immune response. 
The type of the Th immunity is crucial for the outcome of an influenza infection. 
Induction of Th1 response promotes cell-mediated immunity [25], which is important in 
viral clearance and recovery from the infection [38]. Conversely, the Th2 immune 
response enhances humoral immunity, which contributes to neutralization of influenza 
virus and therefore prevention of clinical influenza infection [86]. In our study, an 
IgG2a dominance was observed throughout the experiment in the group immunized with 
adjuvanted vaccine. We found significantly higher Th1 cytokine (IL-2 and IFN-γ) levels 
after the second dose in the adjuvanted than non adjuvanted vaccine formulation. 
Similarly, IL-2 and IFN-γ have been found to dominate the systemic response after 
influenza infection [78]. Formulation of the vaccine with c-di-GMP gives a stronger 
cell-mediated immune response. Our group has previously shown that vaccination of 
mice with one and two doses of whole virus vaccine elicited a predominant IgG2a 
antibody response in sera [90]. Furthermore, the IgG2a is the most potent isotype in the 
immune response to viral infection [88]. Th1 responses are desirable after influenza 
vaccination because they are more cross-protective than Th2 responses. This is due to 
the recognition of highly conserved internal proteins (NP and M) by CTLs [89].  
 
A low IgG2a/IgG1 ratio and much higher Th2 cytokine (IL-4 and IL-5) levels than Th1 
cytokine (INF-γ and IL-2) concentrations were detected in the absence of adjuvant. 
Similar results have also been observed in C57-BL/6 mice and it has been suggested that 
the exclusive induction of IgG1 may be explained by the absence of viral genomes [87]. 
However, others have found that the Th2 response in immunized mice does not confer 
protection against virus replication in the lungs [92]. Therefore, in the current study it 
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would be interesting to determine the protective efficacy by using a highly pathogenic 
H5N1 virus challenge in both groups, immunized with and without c-di-GMP adjuvant. 
 
Our group has earlier shown that mice vaccinated with whole inactivated virus vaccine 
induced a mixed Th1/Th2 cytokine response after the second dose [93]. Interestingly, 
the results of the current study shown that the use of c-di-GMP as mucosal adjuvant 
induced not only high levels of Th1 cytokines, but also proportionally high levels of Th2 
cytokines (IL-4 and IL-5) and a high concentration of IgA antibodies in both locally and 
systematically. This indicates that the presence of the mucosal adjuvant also effectively 
stimulates the humoral immune response.  
 
In the group vaccinated with adjuvanted vaccine, the concentration of IL-10 cytokine 
(Th2 profile) was significantly higher than in the group vaccinated without adjuvant. IL-
10 cytokines are secreted by Th2 cells and contribute to inhibition of cytokine 
production by Th1 cells [79]. On the other hand, Th1 cells can also secret IL-10, but this 
is in order to “self-regulation” [76, 94]. In mice, the function of IL-10 cytokine is 
thought to prevent pathology induced by inflammatory responses. It also enhances 
survival, proliferation and antibody production of B cells [79].  
 
The presence of the c-di-GMP adjuvant induced a significant higher IL-17 than the 
subunit vaccine alone. IL-17 has been shown to be important in the protection against 
bacteria and fungi [82], but not virus. However, IL-17 has a proinflammatory activity, 
which is involved in the recruitment of neutrophils. IL-17 is also able to stimulate Th2 
cytokine production, which may amplify allergic inflammation [42].   
 
A number of other mucosal adjuvants are currently being tested for intranasal 
formulation of vaccines. Different mucosal adjuvant elicits various Th type responses. 
ISCOM and LT stimulate both Th1 and Th2 responses. Cog adjuvant promotes strongly 
Th1 response whilst CT adjuvant stimulates Th2 response [16]. In our study, the 
mucosal c-di-GMP showed to induced mainly Th1 response and a weaker Th2 response. 
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6. Conclusions 
 
In this study, we found that intranasal vaccination with subunit vaccine administered 
with c-di-GMP adjuvant induced a predominant Th1-type response, which may enhance 
the CTL immune response and thus the clearance of the viral infection. In contrast, non-
adjuvanted vaccine elicited a Th2 response, but only low antibody titers. The presence 
of mucosal adjuvant c-di-GMP in the vaccine elicits a significantly more rapid and 
significantly stronger mucosal immune response than subunit vaccine alone. Our study 
confirmed that this formulation induced a stronger humoral and cell-mediated immunity 
in naïve mice as well. The results obtained in this study indicate that c-di-GMP is a 
promising adjuvant for the future development of intranasal pandemic influenza 
vaccines including the current pandemic H1N1 strain. 
 
6.1 Future prospective 
 
- We found that this mucosal adjuvant induced immunological memory and long-lasting 
immunity at 10 weeks post second vaccination. Further work should address the 
duration of the long-lasting immunity. 
 
- C-di-GMP induced high levels of Th1 cytokines and IgG2a, and this may indicate an 
efficient induction of cellular immunity. However, the influenza subunit vaccine 
adjuvanted with c-di-GMP may also induce a cytotoxic response and this should be 
evaluated in a cytotoxicity assay.  
 
- C-di-GMP used as mucosal adjuvant in an intranasal vaccine has shown to induce a 
stronger systemic and mucosal immunity. It will be important to determine the antigen 
to adjuvant ratio which will contribute to mapping the adjuvant’s function and toxicity.  
 
- A lethal challenge after intranasal vaccination with c-di-GMP adjuvant should be 
performed. This will provide a direct evidence of the protective efficacy and allow 
evaluation of the immunological parameters as correlates of protection. 
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- C-di-GMP as a mucosal adjuvant gives a good immune response in mice, but it is 
important to evaluate the adjuvant in other animal species to build a preclinical dossier 
to allow progression to human clinical trial.  
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